Low-level viremia in HIV-1 infection: Consequences and implications for switching to a new regimen

HIV Clinical Trials

Volumn 10, Issue 2, 2009, Pages 116-124

  Cohen, Calvin ^a  

^a Boston Community Research Initiative of New England   (United States)

Author keywords

Antiretroviral; HIV; Regimen; Resistance; Viremia; Virologic failure

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; ETRAVIRINE; INTEGRASE INHIBITOR; MARAVIROC; PROTEINASE INHIBITOR; RALTEGRAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TIPRANAVIR; VIRUS RNA; ANTIRETROVIRUS AGENT;

ANTIVIRAL THERAPY; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; DISEASE COURSE; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; GENE CONTROL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOMODULATION; INFECTION RISK; MULTIDRUG RESISTANCE; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RNA ANALYSIS; TREATMENT RESPONSE; VIREMIA; VIRUS IMMUNITY; VIRUS INHIBITION; VIRUS MUTATION; VIRUS REACTIVATION; VIRUS REPLICATION; VIRUS RESISTANCE; BLOOD; DRUG EFFECT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; TREATMENT FAILURE; VIROLOGY; VIRUS LOAD;

ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; HIV INFECTIONS; HIV-1; HUMANS; RNA, VIRAL; TREATMENT FAILURE; VIRAL LOAD; VIREMIA;

EID: 68149087762     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct1002-116     Document Type: Review

References (61)

1. Hughes MD, Johnson VA, Hirsch MS, et al. Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team. Ann Intern Med. 1997;126(12):929-938.
2. Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997;126(12):946-954.
3. Marschner IC, Collier AC, Coombs RW, et al. Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefi t of antiretroviral therapy. J Infect Dis. 1998;177(1):40-47.
4. Thiébaut R, Morlat P, Jacqmin-Gadda H, et al. Clinical progression of HIV-1 infection according to the viral response during the first year of antiretroviral treatment. Groupe d'Epidémiologie du SIDA en Aquitaine (GECSA). AIDS. 2000;14(8):971-978.
5. Hammer SM, Eron JJ, Reiss P Jr, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society USA Panel. JAMA. 2008;300(5):555-570.
6. Department of Health and Human Services (DHHS). Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. November 3, 2008. Available at: http://aidsinfo.nih.gov/contentfi les/AdultandAdolescentGL.pdf. Accessed January 7, 2009.
7. Gazzard BG, on behalf of the BHIVA Treatment Guidelines Writing Group. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. Available at: http://www.bhiva.org/files/file 1030835.pdf. Accessed January 7, 2009.
8. Coakley EP, Doweiko JP, Bellosillo NA, D'Agata EM, Albrecht MA. HIV drug resistance profi les and clinical and virologic outcomes among HIV-infected subjects with stable detectable plasma viral loads<1000 copies/mL for at least 12 months. Presented at: 9th Conference on Retroviruses and Opportunistic Infections; February 24-28, 2002; Seattle, Washington. Abstract 556-T.
9. Kantor R, Shafer R, Katzenstein D, Follansbee S, Fessel J. Evolution of reverse transcriptase and protease resistance mutations in HIV-1 infected patients on antiretroviral therapy. Presented at: 9th Conference on Retroviruses and Opportunistic Infections; February 24-28, 2002; Seattle, Washington. Abstract 566-T.
10. Hermankova M, Ray SC, Ruff C, et al. HIV-1 drug resistance profiles in children and adults with viral load of<50 copies/mL receiving combination therapy. JAMA. 2001;286(2):196-207.
11. Goetz MB, Moatamed F, Wrin T, Dawson K, Hellmann N. Long term durability of impaired HIV replication capacity (RC) in patients maintained on a stable treatment regimen despite low-level virologic failure (VF). Presented at: 2nd International AIDS Society Conference on Pathogenesis and Treatment; July 13-17, 2003; Paris, France. Abstract 271.
12. Tenorio AR, Smith KY, Kuritzkes DR, et al. HIV-1-infected antiretroviral-treated patients with prolonged partial viral suppression. J Acquir Immune Defi c Syndr. 2003;34(5):491-496.
13. Morse C, Maldarelli F, Dewar R. Limited evolution of drug resistance in HIV-1 infected patients with persistent low-level viremia on a stable regimen for longer than 1 year. Presented at: 12th Conference on Retroviruses and Opportunistic Infections; February 22-25, 2005; Boston, MA. Abstract 678.
14. Sungkanuparph S, Groger R, Overton E, et al. Persistent low-level viraemia and virological failure in HIV-1 infected patients treated with highly active antiretroviral therapy. HIV Med. 2006;7:437-441.
15. Nasta P, Castelnuovo F, Paraninfo G. To maintain or to switch to HAART in heavily pre-treated patients with lowlevel viremia. Presented at: 12th Conference on Retroviruses and Opportunistic Infections; February 22-25, 2005; Boston, MA. Abstract 605.
16. Karlsson AC, Younger SR, Martin JN, et al. Immunologic and virologic evolution during periods of intermittent and persistent low-level viremia. AIDS. 2004;18(7):981-989.
17. Karlsson AC, Younger S, Martin J, et al. Low-level antigenic exposure differentially affects T cell activation and HIV specifi c T cell response. Presented at: 11th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2004; San Francisco, CA. Abstract 453.
18. Sklar PA, Ward DJ, Baker RK, et al. Prevalence and clinical correlates of HIV viremia ("blips") in patients with previous suppression below the limits of quantifi cation. AIDS. 2002;16(15):2035-2041.
19. Greub G, Cozzi-Lepri A, Ledergerber B, et al. Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy. AIDS. 2002;16(14):1967-1969.
20. Nettles RE, Kieffer TL, Simmons RP, et al. Genotypic resistance in HIV-1-infected patients with persistently detectable low-level viremia while receiving highly active antiretroviral therapy. Clin Infect Dis. 2004:39(7):1030-1037.
21. Lafeuillade A, Hittinger G, Delbeke E, Poggi C. Resistance selection with stable low levels of HIV-1 viremia. Presented at: XV International AIDS Conference; July 11-16, 2004; Bangkok, Thailand. Abstract WeOrB1293.
22. Aleman S, Söderbärg K, Visco-Comandini U, Sitbon G, Sönnerborg A. Drug resistance at low viraemia in HIV-1 infected patients with antiretroviral combination therapy. AIDS. 2002;16(7):1039-1044.
23. Deeks SG, Martin JN, Sinclair E, et al. Strong cell-mediated immune responses are associated with the maintenance of low-level viremia in antiretroviral-treated individuals with drug-resistant human immunodefi ciency virus type 1. J Infect Dis. 2004;189(2):312-321.
24. Lo Re V III, Gasink L, Kostman JR, Leonard D, Gross R. Natural history of patients with low-level HIV viremia on antiretroviral therapy. AIDS Patient Care STDs. 2004;18(8):436-442.
25. Ostrowski SR, Katzenstein TL, Thim PT, Pedersen BK, Gerstoft J, Ullum H. Low-level viremia and proviral DNA impede immune reconstitution in HIV-1-infected patients receiving highly active antiretroviral therapy. J Infect Dis. 2005;191(3):348-357.
26. Barbour JD, Wrin T, Grant RM, et al. Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults. J Virol. 2002;76(21):11104-11112.
27. Solas C, Lafeuillade A, Halfon P, Chadapaud S, Hittinger G, Lacarelle B. Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodefi ciency virus-infected patients. Antimicrob Agents Chemother. 2003;47:238-243.
28. Tirado G, Jove G, Kumar R, et al. Differential virus evolution in blood and genital tract of HIV-infected females: evidence for the involvement of drug and non-drug resistance-associated mutations. Virology. 2004;324:577-586.
29. Tirado G, Jove G, Reyes E, et al. Differential evolution of cellassociated virus in blood and genital tract of HIV-infected families undergoing HAART. Virology. 2005;334:299-305.
30. Tirado G, Jove G, Yamamura Y. Vaginal HIV-1 shows distinct drug resistance mutation patterns compared to plasma HIV-1 and remain M-tropic despite advanced disease. Antivir Ther. 2003;8:S75. Abstract 68.
31. Günthard HF, Havlir DV, Fiscus S, et al. Residual human immunodefi ciency virus (HIV) type 1 RNA and DNA in lymph nodes and HIV RNA in genital secretions and in cerebrospinal fl uid after suppression of viremia for 2 years. J Infect Dis. 2001;183:1318-1327.
32. Lafeuillade A, Chollet L, Hittinger G, Profizi N, Costes O, Poggi C. Residual human immunodeficiency virus type 1 RNA in lymphoid tissue of patients with sustained plasma RNA of <200 copies/mL. J Infect Dis. 1998;177(1): 235-238.
33. Mayer KH, Boswell S, Goldstein, et al. Persistence of human immunodefi ciency virus in semen after adding indinavir to combination antiretroviral therapy. Clin Infect Dis. 1999;28:1252-1259.
34. Liuzzi G, Chirianni A, Zaccarelli M, et al. Differences between semen and plasma of nucleoside reverse transcriptase resistance mutations in HIV-infected patients, using a rapid assay. In Vivo. 2004;18:509-512.
35. Cozzi-Lepri A, Phillips AN, Ruiz L, et al. Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen. AIDS. 2007;21:721-732.
36. Napravnik S, Edwards D, Stewart P, et al. HIV-drug resistance evolution among patients on potent combination antiretroviral therapy with detectable viremia. J Acquir Immune Defi c Syndr. 2005;40:34-40.
37. Karlsson AC, Hunt P, Sinclair E, et al. HIV specifi c immunity, T-cell activation and replicative capacity in antiretroviral treated adults experiencing intermittent versus persistent low-level viral replication. Antivir Ther. 2002;7:S43.
38. Deeks, SG, Walker BD. The immune response to AIDS virus infection: good, bad, or both? J Clin Invest. 2004;113(6):808-810.
39. PLATO Collaboration. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet. 2004;364:51-62.
40. Deeks SG, Barbour JD, Martin JN, et al. Sustained CD4+ T cell response after virologic failure of protease inhibitorbased regimens in patients with human immunodefi ciency virus infection. J Infect Dis. 2000;181(3):946-953.
41. Deeks SG, Barbour JD, Grant RM, Martin JN. Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia. AIDS. 2002;16:201-207.
42. Langford SE, Ananworanich J, Cooper DA. Predictors of disease progression in HIV infection: a review. AIDS Res Ther. 2007;4:11.
43. Hazenberg MD, Otto SA, van Benthem BHB, et al. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS. 2003;17:1881-1888.
44. Ruane P, Gallant JE, Tennenberg A, Guzman SS. Safety and effi cacy of darunavir in com low-dose ritonavir: 48-week results from the POWER studies. Presented at: Frontiers in Drug Development for Antiretroviral Therapies (HIV DART); December 10-14, 2006; Cancun, Mexico. Abstract 74.
45. Miralles D, Hill A, Vangeneugden T, Lefebvre E. Durability of HIV RNA endpoints in treatment-experienced patients: analysis of POWER, RESIST and TORO trials. Presented at: 8th International Congress on Drug Therapy in HIV Infection; November 12-16, 2006; Glasgow, UK. Abstract P31.
46. + cell counts and HIV RNA levels during follow-up. J Infect Dis. 2008:197:1145-1155.
47. Tarwater PM, Gallant JE, Mellors JW, et al. Prognostic value of plasma HIV RNA among highly active antiretroviral therapy users. AIDS. 2004;18(18):2419-2423.
48. Lazzarin A, Campbell T, Clotet B, et al. Effi cacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24 week results from a randomized, double-blind, placebo-controlled trial. Lancet. 2007;370:39-48.
49. Madruga JV, Cahn P, Grinsztein B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomized, double-blind, placebo-controlled trial. Lancet. 2007;370:29-38.
50. Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med. 2008;359:339-354.
51. Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med. 2008;359:1429-1441.
52. Johnson M, Campbell T, Clotet B. DUET-2: Week 48 results of a Phase III randomized double-blind trial to evaluate the efficacy and safety of etravirine (ETR; TMC125) versus placebo in 591 treatment-experienced HIV-1-infected patients. Presented at: 15th Conference on Retroviruses and Opportunistic Infections; February 3-6, 2008; Boston, MA. Abstract 791.
53. Haubrich R, Cahn P, Grinsztejn B. DUET-1: Week 48 results of a Phase III randomized double-blind trial to evaluate the effi cacy and safety of etravirine (ETR; TMC125) versus placebo in 612 treatment-experienced HIV-1-infected patients. Presented at: 15th Conference on Retroviruses and Opportunistic Infections; February 3-6, 2008; Boston, MA. Abstract 790.
54. Zaccarelli M, Tozzi V, Forbici F, et al. Achieving undetectable HIV viral load after genotypic resistance test dramatically decreases HIV progression and survival even in more advanced patients. Presented at: 5th European HIV Drug Resistance Workshop; March 28-30, 2007; Cascais, Portugal. Poster 93.
55. Bracciale L, Colafi gli M, Di Giambenedetto S, et al. Reaching undetectable HIV RNA levels is an independent predictor of AIDS-free survival in patients with 3-class resistant HIV-1. Presented at: 5th European HIV Drug Resistance Workshop; March 28-30, 2007; Cascais, Portugal. Poster 90.
56. Kousignian I, Abgrall S, Grabar S, et al. Maintaining antiretroviral therapy reduces the risk of AIDS-defi ning events in patients with uncontrolled viral replication and profound immunodeficiency. Clin Infect Dis. 2008 Jan 15;46(2):296-304.
57. Danel C, Moh R, Minga A, et al. CD4-guided structured antiretroviral treatment interruption strategy in HIV- infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial. Lancet. 2006;367:1981-1989.
58. Clotet B, Bellos N, Molina JM, et al. Effi cacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet. 2007;369:1169-1178.
59. Madruga JV, Berger D, McMurchie M, et al. Effi cacy and safety of darunavir-ritonavir compared with that of lopinavirritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomized controlled phase III trial. Lancet. 2007;370:49-58.
60. Saag M, Ive P, Heera J, et al. A multicenter, randomised, double-blind, comparative trial of a novel CCR5 antagonist, maraviroc versus efavirenz, both in combination with Combivir (zidovudine [ZDV]/lamivudine [3TC]), for the treatment of antiretroviral naive subjects infected with R5 HIV-1: Week 48 results of the MERIT study. Presented at: 4th International AIDS Society (IAS) Conference; July 22-25, 2007; Sydney, Australia. Abstract WESS104.
61. Alatrakchi N, Duvivier C, Costagliola D, et al. Persistent low viral load on antiretroviral therapy is associated with T cell-mediated control of HIV replication. AIDS. 2005;19(1):25-33.